| Título: | Can Biomarkers Improve Ability of NPI in Risk Prediction? A Decision Tree Model Analysis |
| Autores: |
Baneshi, Mohammad Reza; 1. Health School, Kerman Medical University, Department of Biostatistics and Epidemiology, Kerman, Iran
2. Centre for Population Health Sciences, University of Edinburgh, Teviot Place, Edinburgh, UK Warner, P; Centre for Population Health Sciences, University of Edinburgh, Teviot Place, Edinburgh, UK Anderson, N; Centre for Population Health Sciences, University of Edinburgh, Teviot Place, Edinburgh, UK Tovey, S; Section of Surgical and Translational Sciences, Division of Cancer Sciences and Molecular Pathology, Glasgow Royal Infirmary, Glasgow, UK Edwards, J; Section of Surgical and Translational Sciences, Division of Cancer Sciences and Molecular Pathology, Glasgow Royal Infirmary, Glasgow, UK Bartlett, JMS; Endocrine Cancer Group, University of Edinburgh, Edinburgh Cancer Research Centre, Western General Hospital, Crewe Road South, Edinburgh, UK |
| Fecha: | 2012-04-02 |
| Publicador: | Shahid Beheshti University of Medical Sciences |
| Fuente: |
Ver documento |
| Tipo: |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
| Tema: | Breast neoplasm; Tissue microarray data; NPI; Tree-based survival methods; Missing data |
| Descripción: | Background: The Nottingham Prognostic Index (NPI) is widely-used in the UK for risk stratification of breast cancer patients. This paper aims to evaluate the ability of this index to detect patients with sufficiently low risk of recurrence that they could be spared harsh treatments, and to construct an enhanced prognostic rule that integrates biomarkers with clinical variables to achieve better risk stratification. Methods: We undertook review of published studies of outcomes in risk groups derived by applying NPI, and report estimated event-free rates extracted from papers found. Then we analysed biological and clinical variables for 401 ER+ patients, to develop a Tree-based Survival Model (TSM), for risk prediction, and estimated event-free rates by resulting risk-groups, Kaplan-Meier (K-M) curves corresponding to TSM and NPI were plotted. Results: We concluded that NPI does not distinguish low risk patients with a sufficiently high event-free rate to make it likely clinicians would decide treatments with potential harmful side effects can be avoided in that group. On the other hand, in the decision tree constructed, utilising 3 biomarkers, nodal status and tumour size, the 4 risk groups were clearly diverged in terms of event-free rates. Conclusion: There is considerable potential for improved prognostic modelling by incorporation of biological variables into risk prediction. Whilst low risk patients identified by our TSM model could potentially avoid systemic treatment, higher risk patients might require additional treatment, including chemotherapy or other adjuvant treatment options. However, the decision tree model needs to be validated in a larger clinical trial cohort. Keywords: Breast neoplasm; Tissue microarray data; NPI; Tree-based survival methods; Missing dataReferences 1. McPherson K, Steel CM, Dixon JM. ABC of breast diseases. Breast cancer-epidemiology, risk factors, and genetics. BMJ 2000 Sep 9; 321(7261):624-8. 2. Cancer Research UK. Breast Cancer: UK breast cancer statistics. http://info cancerresearchuk org/cancerstats/types/breast/ 2006 November [cited 2007 Feb 26]; Available from: URL: http://info.cancerresearchuk.org/ cancerstats/ types/ breast/ 3. Altman DG, Lyman GH. Methodological challenges in the evaluation of prognostic factors in breast cancer. Breast Cancer Res Treat 1998; 52(1-3):289-303. 4. Haybittle JL, Blamey RW, Elston CW, Johnson J, Doyle PJ, Campbell FC, et al. A prognostic index in primary breast cancer. Br J Cancer 1982 Mar; 45(3):361-6. 5. Todd JH, Dowle C, Williams MR, Elston CW, Ellis IO, Hinton CP, et al. Confirmation of a prognostic index in primary breast cancer. Br J Cancer 1987 Oct; 56(4):489-92. 6. Galea MH, Blamey RW, Elston CE, Ellis IO. The Nottingham Prognostic Index in primary breast cancer. Breast Cancer Res Treat 1992; 22(3):207-19. 7. Balslev I, Axelsson CK, Zedeler K, Rasmussen BB, Carstensen B, Mouridsen HT. The Nottingham Prognostic Index applied to 9,149 patients from the studies of the Danish Breast Cancer Cooperative Group (DBCG). Breast Cancer Res Treat 1994; 32(3):281-90. 8. Lee AH, Ellis IO. The nottingham prognostic index for invasive carcinoma of the breast. Pathol Oncol Res 2008; 14(2):113-5. 9. Kirkegaard T, Bartlett JM. Novel pharmacodiagnostics in breast cancer. European oncological disease 2006; 53-6. 10. Martin M. Molecular biology of breast cancer. Clin Transl Oncol 2006 Jan; 8(1):7-14. 11. Chen W, Foran DJ. Advances in cancer tissue microarray technology: Towards improved understanding and diagnostics. Anal Chim Acta 2006 Mar 30; 564(1):74-81. 12. Peduzzi P, Concato J, Feinstein AR, Holford TR. Importance of events per independent variable in proportional hazards regression analysis. II. Accuracy and precision of regression estimates. J Clin Epidemiol 1995 Dec; 48(12):1503-10. 13. Therneau TM, Atkinson EJ. An interoduction to recursive partitioning using the rpart routine. 1997 Feb 11. 14. McGlynn LM, Kirkegaard T, Edwards J, Tovey S, Cameron D, Twelves C, et al. Ras/Raf-1/MAPK pathway mediates response to tamoxifen but not chemotherapy in breast cancer patients. Clin Cancer Res 2009 Feb 15; 15(4):1487-95. 15. Kirkegaard T, McGlynn LM, Campbell FM, Muller S, Tovey SM, Dunne B, et al. Amplified in breast cancer 1 in human epidermal growth factor receptor - positive tumors of tamoxifen-treated breast cancer patients. Clin Cancer Res 2007 Mar 1; 13(5):1405-11. 16. Kirkegaard T, Witton CJ, McGlynn LM, Tovey SM, Dunne B, Lyon A, et al. AKT activation predicts outcome in breast cancer patients treated with tamoxifen. J Pathol 2005 Oct; 207(2):139-46. 17. Baneshi MR. Statistical Models in Prognostic Modelling of Many Skewed Variables and Missing Data: A Case Study in Breast Cancer (PhD thesis submitted at Edinburgh University) 2009. 18. Williams BA, Mandrekar JN, Mandrekar SJ, Cha SS, Furth AF. Finding optimal cutpoints for continuous covariates with binary and time-to-event outcomes. 2006. 19. Clark TG, Bradburn MJ, Love SB, Altman DG. Survival analysis part IV: further concepts and methods in survival analysis. Br J Cancer 2003 Sep 1; 89(5):781-6. 20. Altman DG, Lausen B, Sauerbrei W, Schumacher M. Dangers of using "optimal" cutpoints in the evaluation of prognostic factors. J Natl Cancer Inst 1994 Jun 1; 86(11):829-35. 21. Radespiel-Troger M, Rabenstein T, Schneider HT, Lausen B. Comparison of tree-based methods for prognostic stratification of survival data. Artif Intell Med 2003 Jul; 28(3):323-41. 22. Dannegger F. Tree stability diagnostics and some remedies for instability. Stat Med 2000 Feb 29; 19(4):475-91. 23. Segal MR, Bloch DA. A comparison of estimated proportional hazards models and regression trees. Stat Med 1989 May; 8(5):539-50. 24. Banerjee M, George J, Song EY, Roy A, Hryniuk W. Tree-based model for breast cancer prognostication. J Clin Oncol 2004 Jul 1; 22(13):2567-75. 25. Bloom HJ, Richardson WW. Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer 1957 Sep; 11(3):359-77. 26. Van Buuren S, Boshuizen HC, Knook DL. Multiple imputation of missing blood pressure covariates in survival analysis. Stat Med 1999 Mar 30; 18(6):681-94. 27. Van Buuren S, Oudshoorn K. Multiple imputation by chained equations: MICE V1.0 User's manual. 2000. 28. Blamey RW, Ellis IO, Pinder SE, Lee AH, Macmillan RD, Morgan DA, et al. Survival of invasive breast cancer according to the Nottingham Prognostic Index in cases diagnosed in 1990-1999. Eur J Cancer 2007 Jul; 43(10):1548-55. 29. Blamey RW, Pinder SE, Ball GR, Ellis IO, Elston CW, Mitchell MJ, et al. Reading the prognosis of the individual with breast cancer. Eur J Cancer 2007 Jul; 43(10):1545-7. 30. Sauerbrei W, Hubner K, Schmoor C, Schumacher M. Validation of existing and development of new prognostic classification schemes in node negative breast cancer. German Breast Cancer Study Group. Breast Cancer Res Treat 1997 Jan; 42(2):149-63. 31. Coradini D, Boracchi P, Daidone MG, Pellizzaro C, Miodini P, Ammatuna M, et al. Contribution of vascular endothelial growth factor to the Nottingham prognostic index in node-negative breast cancer. Br J Cancer 2001 Sep 14; 85(6):795-7. 32. Okugawa H, Yamamoto D, Uemura Y, Sakaida N, Yamada M, Tanaka K, et al. Prognostic factors in breast cancer: the value of the Nottingham Prognostic Index for patients treated in a single institution. Surg Today 2005; 35(11):907-11. 33. Kollias J, Murphy CA, Elston CW, Ellis IO, Robertson JF, Blamey RW. The prognosis of small primary breast cancers. Eur J Cancer 1999 Jun; 35(6):908-12. 34. Ring BZ, Seitz RS, Beck R, Shasteen WJ, Tarr SM, Cheang MC, et al. Novel prognostic immunohistochemical biomarker panel for estrogen receptor-positive breast cancer. J Clin Oncol 2006 Jul 1; 24(19):3039-47. 35. Lundin J, Lehtimaki T, Lundin M, Holli K, Elomaa L, Turpeenniemi-Hujanen T, et al. Generalisability of survival estimates for patients with breast cancer--a comparison across two population-based series. Eur J Cancer 2006 Dec; 42(18):3228-35. 36. Sidoni A, Bellezza G, Cavaliere A, Del SR, Scheibel M, Bucciarelli E. Prognostic indexes in breast cancer: comparison of the Nottingham and Adelaide indexes. Breast 2004 Feb; 13(1):23-7. 37. Eden P, Ritz C, Rose C, Ferno M, Peterson C. "Good Old" clinical markers have similar power in breast cancer prognosis as microarray gene expression profilers. Eur J Cancer 2004 Aug; 40(12):1837-41. 38. D'Eredita' G, Giardina C, Martellotta M, Natale T, Ferrarese F. Prognostic factors in breast cancer: the predictive value of the Nottingham Prognostic Index in patients with a long-term follow-up that were treated in a single institution. Eur J Cancer 2001 Mar;37(5):591-6. 39. Brown J, Jones M, Benson EA. Comment on the Nottingham Prognostic Index. Breast Cancer Res Treat 1993; 25(3):283. 40. Callagy GM, Pharoah PD, Pinder SE, Hsu FD, Nielsen TO, Ragaz J, et al. Bcl-2 is a prognostic marker in breast cancer independently of the Nottingham Prognostic Index. Clin Cancer Res 2006 Apr 15; 12(8):2468-75. 41. Baneshi MR, Warner P, Anderson N, Bartlett JSM. Tamoxifen resistance in early breast cancer: statistical modelling of tissue markers to improve risk prediction. Br J Cancer 2010; 102: 1503-10. 42. Lausen B, Horton T, Bertz F, Schumacher M. Assessment of optimal selected prognostic factors. Biometrical Journal 2004; 46:364-74. 43. Hothorn T, Lausen B, Benner A, Radespiel-Troger M. Bagging survival trees. Stat Med 2004 Jan 15;23(1):77-91. 44. Steyerberg EW, Harrell FE, Jr., Borsboom GJ, Eijkemans MJ, Vergouwe Y, Habbema JD. Internal validation of predictive models: efficiency of some procedures for logistic regression analysis. J Clin Epidemiol 2001 Aug; 54(8):774-81. 45. Burton A, Altman DG. Missing covariate data within cancer prognostic studies: a review of current reporting and proposed guidelines. Br J Cancer 2004 Jul 5; 91(1):4-8. 46. Kristman VL, Manno M, Cote P. Methods to account for attrition in longitudinal data: do they work? A simulation study. Eur J Epidemiol 2005; 20(8):657-62. 47. Abe O, Abe R, Enomoto K, Kikuchi K, Koyama H, Masuda H, et al. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005 May 14; 365(9472):1687-717. 48. Justice AC, Covinsky KE, Berlin JA. Assessing the generalizability of prognostic information. Ann Intern Med 1999 Mar 16; 130(6):515-24. 49. Faratian D, Bartlett JM. Predictive markers in breast cancer--the future. Histopathology 2008 Jan; 52(1):91-8. 50. Cannings E, Kirkegaard T, Tovey SM, Dunne B, Cooke TG, Bartlett JM. Bad expression predicts outcome in patients treated with tamoxifen. Breast Cancer Res Treat 2007 Apr; 102(2):173-9. 51. Tovey SM, Dunne B, Witton CJ, Forsyth A, Cooke TG, Bartlett JM. Can molecular markers predict when to implement treatment with aromatase inhibitors in invasive breast cancer? Clin Cancer Res 2005 Jul 1; 11(13):4835-42. 52. Harrell FE, Margolis PA, Gove S, Mason KE, Mulholland EK, Lehmann D, et al. Development of a clinical prediction model for an ordinal outcome: the World Health Organization Multicentre Study of Clinical Signs and Etiological agents of Pneumonia, Sepsis and Meningitis in Young Infants. WHO/ARI Young Infant Multicentre Study Group. Stat Med 1998 Apr 30; 17(8):909-44. 53. Ciampi A, Lawless JF, McKinney SM, Singhal K. Regression and recursive partition strategies in the analysis of medical survival data. J Clin Epidemiol 1988; 41(8):737-48. 54. Ture M, Tokatli F, Kurt I. Using Kaplan-Meier analysis together with decision tree methods (C&RT, CHAID, QUEST, C4.5 AND ID3) in determining recurrence free survival of breast cancer patients. Expert Systems with Applications 2009; 36:2017-26. |
| Idioma: | Inglés |
1 Health and Education - 2 por Akbari, Mohammad Esmaeil | 6 Effectiveness of Mindfulness-Based Cognitive Therapy on Reduction of Depression and Anxiety Symptoms in Mothers of Children With Cancer por Mehranfar, Mojtaba; Dept. of Counselling, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran,Younesi, Jalal; Dept. of Counselling, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran,Banihashem, Abdollah; Dept. of Internal Medicine and Paediatrics, University of
Medical Sciences, Mashhad, Iran |
2 The Study of DNA Methylation of bax Gene Promoter in Breast and Colorectal Carcinoma Cell Lines por Alipour, Mohsen; Dept. of Cell and Molecular Biology, School of Biology, College of Science, University of Tehran, Tehran, Iran,Zargar, Seyed Jalal; Dept. of Cell and Molecular Biology, School of Biology, College of Science, University of Tehran, Tehran, Iran,Safarian, Shahrokh; Dept. of Cell and Molecular Biology, School of Biology, College of Science, University of Tehran, Tehran, Iran,Fouladdel, Shamile; Dept. of Pharmacology and Toxicology, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran,Azizi, Ebrahim; Dept. of Pharmacology and Toxicology, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
Biotechnology Research Center, Tehran University of Medical Sciences, Tehran, Iran,Jafargholizadeh, Naser; Dept. of Cell & Molecular Biology, School of Biology, College of Science, University of Tehran, Tehran, Iran | 7 Prevention and Management of Mucositis in Patients With Cancer: a Review Article por [wlia, ّatemeh; Dept. of Oral Medicine, Yazd Shahid Sadoughi University of Medical Sciences, Yazd, Iran,«azemeini, ُeidkazem; Burn hospital, Yazd Shahid Sadoughi University of Medical Sciences, Yazd, Iran,gholami, neda; Dept. of Oral Medicine, Yazd Shahid Sadoughi University of Medical Sciences, Yazd, Iran |
3 Cancer Prevention; Cancer Risk Management por Akbari, Mohammad Esmaeil | 8 Psychosocial Care for Breast Cancer: Physicians' Perspective por Kaviani, Ahmad; Department of surgery, Tehran University of Medical Sciences, Tehran, Iran,Mehrdad, N; Iranian Center for Breast Cancer (ICBC), Academic Center for Education, Culture and Research (ACECR), Tehran, Iran,Yunesian, M; school of Public Health , Environmental Research Center, Tehran University of Medical Sciences, Tehran, Iran,Shakiba, B; Students’ Scientific Research Center, Tehran University of Medical Sciences, Tehran, Iran,Ebrahimi, M; Iranian Center for Breast Cancer (ICBC), Academic Center for Education, Culture and Research (ACECR), Tehran, Iran,Majidzadeh, K; Iranian Center for Breast Cancer (ICBC), Academic Center for Education, Culture and Research (ACECR), Tehran, Iran,Akbari, ME; Cancer Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran |
4 Euthanasia in Cancer Patients, Islamic Point of View por Mousavi, SM; Cancer Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran,Akbari, A; Cancer Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran,Akbari, ME; Cancer Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran,Najd Sepas, H; Cancer Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran | 9 Cell Survival Entropy and Cellular Resistance Activation Dose: Effect of Calprotectin on Gastric Adenocarcinoma Cell Line por Rezaei-Tavirani, Mostafa,Rahmati-Roodsari, Mohammad,Mirzaie, Mehdi,Amini Geram, Pooneh,Sobhi, Sara |
5 Evaluation of Prognostic Factors In Patients with Metastatic Breast Cancer por Saeidi Saedi, H,Seilanian Toosi, M,Mirsadraei, M,Roodbari, S | 10 Antiphospholipid Antibodies in Neoplastic Patients por Mortazavizadeh, MR,Sadeghmanesh, R |